WCM Investment Management LLC Buys 32,126 Shares of Repligen Co. (NASDAQ:RGEN)

WCM Investment Management LLC lifted its position in Repligen Co. (NASDAQ:RGEN) by 47.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 99,158 shares of the biotechnology company’s stock after purchasing an additional 32,126 shares during the quarter. WCM Investment Management LLC owned about 0.18% of Repligen worth $14,470,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in RGEN. Vanguard Group Inc. boosted its position in shares of Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after acquiring an additional 21,719 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after buying an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after buying an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Repligen by 240.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after buying an additional 425,061 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Repligen by 14.4% during the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after buying an additional 71,274 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $139.51 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The firm has a market cap of $7.81 billion, a PE ratio of -3,487.75, a price-to-earnings-growth ratio of 4.04 and a beta of 0.96. The firm’s 50 day simple moving average is $141.56 and its 200-day simple moving average is $145.05. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several analyst reports. Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Wells Fargo & Company started coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. Finally, JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.